PL3373910T3 - Preparat echinomycyny, sposób wytwarzania i sposób stosowania - Google Patents
Preparat echinomycyny, sposób wytwarzania i sposób stosowaniaInfo
- Publication number
- PL3373910T3 PL3373910T3 PL16864923.4T PL16864923T PL3373910T3 PL 3373910 T3 PL3373910 T3 PL 3373910T3 PL 16864923 T PL16864923 T PL 16864923T PL 3373910 T3 PL3373910 T3 PL 3373910T3
- Authority
- PL
- Poland
- Prior art keywords
- echinomycin
- formulation
- making
- echinomycin formulation
- Prior art date
Links
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 title 1
- 108010009858 Echinomycin Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253257P | 2015-11-10 | 2015-11-10 | |
| PCT/US2016/061157 WO2017083403A1 (en) | 2015-11-10 | 2016-11-09 | Echinomycin formulation, method of making and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3373910T3 true PL3373910T3 (pl) | 2023-10-09 |
Family
ID=58695179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16864923.4T PL3373910T3 (pl) | 2015-11-10 | 2016-11-09 | Preparat echinomycyny, sposób wytwarzania i sposób stosowania |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11116726B2 (pl) |
| EP (1) | EP3373910B1 (pl) |
| JP (1) | JP7017018B2 (pl) |
| KR (1) | KR20180101340A (pl) |
| CN (1) | CN108495619A (pl) |
| AU (1) | AU2016352874B2 (pl) |
| CA (1) | CA3004939A1 (pl) |
| ES (1) | ES2956013T3 (pl) |
| PL (1) | PL3373910T3 (pl) |
| SG (1) | SG11201803915UA (pl) |
| WO (1) | WO2017083403A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10898522B2 (en) * | 2015-08-19 | 2021-01-26 | Children's Research Institute, Children's National Medical Center | Compositions and methods for treating graft versus host disease |
| WO2017115358A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| CN108926533B (zh) * | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| PL3646854T3 (pl) * | 2018-10-30 | 2023-01-02 | Polyplus Transfection | Kompozycje do transfekcji mrna do komórki i ich zastosowania |
| JP7378929B2 (ja) * | 2018-12-27 | 2023-11-14 | 花王株式会社 | リポソームの製造方法 |
| US20240033317A1 (en) * | 2020-02-14 | 2024-02-01 | Children's National Medical Center | Uses of hypoxia-inducible factor inhibitors for treating tp53-mutated acute myeloid leukemia |
| CN114432328A (zh) * | 2020-11-05 | 2022-05-06 | 广州中医药大学第一附属医院 | 一种用于治疗肝细胞癌的药物组合物及其应用 |
| WO2022221431A1 (en) * | 2021-04-14 | 2022-10-20 | OncoC4, Inc. | Use of hif-1-alpha inhibitors in cancer immunotherapy |
| WO2024002385A1 (zh) * | 2022-08-05 | 2024-01-04 | 成都华昊中天药业有限公司 | 棘霉素类抗生素胶束及其制备方法和用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4873088A (en) * | 1983-09-06 | 1989-10-10 | Liposome Technology, Inc. | Liposome drug delivery method and composition |
| US5139803A (en) * | 1989-02-09 | 1992-08-18 | Nabisco, Inc. | Method and liposome composition for the stabilization of oxidizable substances |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| AU1297899A (en) * | 1997-10-31 | 1999-05-24 | Walter Reed Army Institute Of Research | Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US20160058793A1 (en) * | 1999-08-30 | 2016-03-03 | David S. Terman | Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer |
| US7259004B1 (en) * | 2002-04-03 | 2007-08-21 | Montana State University | Endophytic streptomycetes from higher plants with biological activity |
| GB2395097B (en) * | 2002-11-07 | 2005-11-09 | Motorola Inc | A decoder apparatus and method of decoding therefor |
| CA2506746A1 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| EP1631669A2 (en) * | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| US20050129753A1 (en) * | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
| US20080103213A1 (en) * | 2004-03-05 | 2008-05-01 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of neurofibromatosis |
| CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| US20070105756A1 (en) * | 2005-10-31 | 2007-05-10 | May Thomas B | Vancomycin formulations having reduced amount of histamine |
| CA2666507A1 (en) | 2006-10-16 | 2008-04-24 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University | Synthetic antibodies |
| US20090053769A1 (en) * | 2007-06-18 | 2009-02-26 | University Of Southern California | Heterologous production of natural products in bacteria |
| MX2010004389A (es) * | 2007-10-23 | 2010-05-20 | Transave Inc | Formulaciones de vancomicina liposomales. |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| LT2506840T (lt) * | 2009-12-04 | 2021-06-25 | OncoC4, Inc. | Hipoksija sukeliančio faktoriaus inhibitorių naudojimas |
| CN107261110A (zh) * | 2010-06-19 | 2017-10-20 | 健康科学西部大学 | Peg化脂质体包封的糖肽抗生素的新制剂 |
| MX2013005046A (es) | 2010-11-03 | 2013-12-12 | Immunogen Inc | Agentes citotoxicos que comprenden nuevos derivados de ansamitocina. |
| JP2014532697A (ja) * | 2011-11-04 | 2014-12-08 | エンセラドゥス ファーマセウティカルス べー．フェー． | ヒトにおける炎症性障害の治療用リポソームコルチコステロイド |
| WO2013070872A1 (en) * | 2011-11-08 | 2013-05-16 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for x-ray induced release from ph sensitive liposomes |
| CN103157112B (zh) * | 2011-12-19 | 2014-12-17 | 沈阳药科大学 | 唾液酸衍生物在制备peg脂质衍生物修饰制剂中的应用 |
| WO2014059031A2 (en) * | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors in the prevention and treatment of inflammation |
| JP6341987B2 (ja) * | 2013-03-13 | 2018-06-13 | マリンクロッド エルエルシー | がん治療のためのリポソームオキサリプラチン組成物 |
| WO2015017807A1 (en) | 2013-08-01 | 2015-02-05 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
| TWI656887B (zh) * | 2013-12-24 | 2019-04-21 | 國邑藥品科技股份有限公司 | 脂質體懸浮液及其製備方法與應用 |
-
2016
- 2016-11-09 WO PCT/US2016/061157 patent/WO2017083403A1/en not_active Ceased
- 2016-11-09 CN CN201680078445.9A patent/CN108495619A/zh active Pending
- 2016-11-09 JP JP2018543294A patent/JP7017018B2/ja not_active Expired - Fee Related
- 2016-11-09 ES ES16864923T patent/ES2956013T3/es active Active
- 2016-11-09 EP EP16864923.4A patent/EP3373910B1/en active Active
- 2016-11-09 US US15/774,217 patent/US11116726B2/en active Active
- 2016-11-09 KR KR1020187016368A patent/KR20180101340A/ko not_active Ceased
- 2016-11-09 PL PL16864923.4T patent/PL3373910T3/pl unknown
- 2016-11-09 SG SG11201803915UA patent/SG11201803915UA/en unknown
- 2016-11-09 CA CA3004939A patent/CA3004939A1/en active Pending
- 2016-11-09 AU AU2016352874A patent/AU2016352874B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US11116726B2 (en) | 2021-09-14 |
| AU2016352874A1 (en) | 2018-06-07 |
| KR20180101340A (ko) | 2018-09-12 |
| CN108495619A (zh) | 2018-09-04 |
| CA3004939A1 (en) | 2017-05-18 |
| EP3373910A1 (en) | 2018-09-19 |
| EP3373910C0 (en) | 2023-07-12 |
| JP2018533628A (ja) | 2018-11-15 |
| JP7017018B2 (ja) | 2022-02-08 |
| US20180344642A1 (en) | 2018-12-06 |
| WO2017083403A1 (en) | 2017-05-18 |
| EP3373910A4 (en) | 2019-06-12 |
| EP3373910B1 (en) | 2023-07-12 |
| AU2016352874B2 (en) | 2021-06-24 |
| SG11201803915UA (en) | 2018-06-28 |
| ES2956013T3 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| ZA201801511B (en) | Flavonoid compositions and methods of use | |
| IL256621A (en) | Carrier-binder preparations and methods for their preparation and use | |
| IL250744A0 (en) | A method for preparing flavociclib and its pharmaceutical preparations | |
| ZA201701244B (en) | Carrier-antibody compositions and methods of making and using the same | |
| IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| PL3373910T3 (pl) | Preparat echinomycyny, sposób wytwarzania i sposób stosowania | |
| GB201514760D0 (en) | Compounds and method of use | |
| GB201519128D0 (en) | Solid forms and methods of preparing the same | |
| IL258139A (en) | Nicotine compositions and methods for their preparation and use | |
| PT3398598T (pt) | Derivado de sulfonamida e método de preparação e utilização do mesmo | |
| IL254783B (en) | Combinations for deworming methods for using them | |
| SG11201705085UA (en) | Polymer composition, its method of preparation, its use and composition comprising it | |
| SG11201803284YA (en) | Novel method of use and compositions | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| SG10201603101YA (en) | Lubricant composition, and preparation method and use thereof | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| SG11201805810PA (en) | Extended, delayed and immediate release formulation method of manufacturing and use thereof | |
| PL3118240T3 (pl) | Sposób otrzymywania bezizocyjanianowych polihydroksyuretanów oraz bezizocyjanianowych polihydroksyuretano-epoksydów | |
| GB201506808D0 (en) | Bottle and method of preparation thereof | |
| GB201408171D0 (en) | Formulation and method of manufacture | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| ZA201708339B (en) | Primin derivatives, method of preparation thereof and use thereof | |
| GB201501469D0 (en) | Garment and method of use thereof |